| __timestamp | Biogen Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 305409000 |
| Thursday, January 1, 2015 | 2113100000 | 377080000 |
| Friday, January 1, 2016 | 1947900000 | 432829000 |
| Sunday, January 1, 2017 | 1935500000 | 496079000 |
| Monday, January 1, 2018 | 2106300000 | 557616000 |
| Tuesday, January 1, 2019 | 2374700000 | 658498000 |
| Wednesday, January 1, 2020 | 2504500000 | 770456000 |
| Friday, January 1, 2021 | 2674300000 | 840100000 |
| Saturday, January 1, 2022 | 2403600000 | 944700000 |
| Sunday, January 1, 2023 | 2549700000 | 1136600000 |
| Monday, January 1, 2024 | 2403700000 | 1464300000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals and Biogen Inc. have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Biogen's SG&A expenses have consistently been higher, averaging around 2.3 billion annually. In contrast, Vertex has maintained a leaner structure, with expenses averaging approximately 652 million, about 28% of Biogen's costs. Notably, Vertex's SG&A expenses have grown by 272% over this period, reflecting strategic investments in growth. Meanwhile, Biogen's expenses have increased by only 14%, indicating a more stable cost structure.
This data highlights the strategic choices each company makes in balancing cost management with growth initiatives, offering valuable insights for investors and industry analysts alike.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Sanofi vs Biogen Inc.
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Biogen Inc. vs Dr. Reddy's Laboratories Limited Trends and Insights
SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Biogen Inc. or Supernus Pharmaceuticals, Inc.